RecruitingPhase 2NCT06758700

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Enrollment

15 participants

Start Date

Feb 7, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Neoplasms Thoracic Neoplasms Lung Diseases Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Summary

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether the chemotherapy drug teniposide can help people with advanced (extensive-stage) small cell lung cancer (SCLC) that is driven by a gene called c-Myc and has stopped responding to prior treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have extensive-stage small cell lung cancer - Your tumor is c-Myc-driven (confirmed by testing) - You have already received at least one prior chemotherapy treatment - You are in good health (ECOG score 0 or 1) with at least one measurable tumor - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have no measurable tumors on imaging - You have other severe ongoing organ diseases - You are planning a pregnancy or currently pregnant or breastfeeding - You cannot follow the study protocol Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTeniposide administration

Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 3-5 consecutive days, with 21 days as one cycle of treatment.